Effect of supramucosal height of a scan body and implant angulation on the accuracy of intraoral scanning: An in vitro study.

STATEMENT OF PROBLEM: Intraoral scanners (IOSs) provide a digital alternative to conventional implant impression techniques. However, the effect of the supramucosal height of the scan body and implant angulation on the accuracy of IOSs remains unclear. PURPOSE: The purpose of this in vitro study was to measure the impact of the supramucosal height of the scan body and implant angulation on the accuracy (trueness and precision) of intraoral digital implant scans in partially edentulous models. MATERIAL AND METHODS: Two maxillary partially edentulous casts with 4 implant analogs were fabricated, 1 with 4 parallel implants (P-groups) and 1 with 2 implants distally inclined 18 degrees (A-groups). An implant scan body was positioned on each implant analog (CARES RC Mono Scanbody). For each cast, 3 subgroups were determined based on the soft tissue moulage fabricated for each reference cast exposing 3 mm (P-3 and A-3 subgroups), 5 mm (P-5 and A-5 subgroups), and 7 mm (P-7 and A-7 subgroups) of the implant scan bodies. The 2 reference casts were registered by using a coordinate measurement machine and desktop scanner (7 Series Dental Wings) and then scanned using an IOS (TRIOS 4) (n=15). Linear and angular discrepancy values and root mean square (RMS) error values between the implant scan bodies measured on the reference and experimental scans were computed with an inspection software program (Geomagic). Mann-Whitney U tests with Bonferroni correction were applied for planned comparisons (α=.05/9 ≈ .006). RESULTS: For linear discrepancies, statistically significant differences were found between groups P-3 and A-3 (P=.004) and between P-7 and A-7 (P=.005). For angular discrepancies, statistically significant differences were found between groups A-3 and A-5 (P=.002) and between P-7 and A-7 (P=.003). The RMS error analysis found no statistically significant differences among the groups. CONCLUSIONS: Implant angulation of 18 degrees did not significantly affect the accuracy of the intraoral scans in terms of 6 of the 9 planned comparisons, although the angled groups had lower mean values. Also, the supramucosal height of the scan body did not significantly affect the accuracy of the intraoral scans in terms of 17 of the 18 planned comparisons. Results may vary with different implant scan body designs.

Carbonic Anhydrase IX: A Renewed Target for Cancer Immunotherapy.

The carbonic anhydrase isoform IX (CAIX) enzyme is constitutively overexpressed in the vast majority of clear cell renal cell carcinoma (ccRCC) and can also be induced in hypoxic microenvironments, a major hallmark of most solid tumors. CAIX expression is restricted to a few sites in healthy tissues, positioning this molecule as a strategic target for cancer immunotherapy. In this review, we summarized preclinical and clinical data of immunotherapeutic strategies based on monoclonal antibodies (mAbs), fusion proteins, chimeric antigen receptor (CAR) T, and NK cells targeting CAIX against different types of solid malignant tumors, alone or in combination with radionuclides, cytokines, cytotoxic agents, tyrosine kinase inhibitors, or immune checkpoint blockade. Most clinical studies targeting CAIX for immunotherapy were performed using G250 mAb-based antibodies or CAR T cells, developed primarily for bioimaging purposes, with a limited clinical response for ccRCC. Other anti-CAIX mAbs, CAR T, and NK cells developed with therapeutic intent presented herein offered outstanding preclinical results, justifying further exploration in the clinical setting.

Supplementation of glycerol or fructose via drinking water to enhance marbling deposition and meat quality of finishing cattle.

Thirty-six Angus-cross steers (667 ± 34.4 kg initial BW, 24.5 mo) were used to assess the impact of short-term glycerin or high-fructose corn syrup administration via drinking water on meat quality and marbling deposition. Steers blocked by BW (3 blocks) were assigned randomly to 1 of 3 drinking water treatments: 1) control (CON), 2) 4.3% crude glycerin (GLYC), or 3) 4.3% high-fructose corn syrup (HFCS) for the final 25 d before slaughter. Average daily gain was lower ( = 0.01) and final live weight was lower ( < 0.01) with HFCS administration compared with CON. Dry matter intake and water intake did not differ among treatments. Fat thickness, muscle depth, and intramuscular fat measured by ultrasound did not differ among treatments. Crude glycerin or HFCS via water supplementation did not alter HCW, dressing percentage, rib eye area, fat thickness, KPH, skeletal maturity, or marbling score. Longissimus muscle and subcutaneous fat color (L*, a*, and b*) were not affected by drinking water treatment. Total lipid content, total fatty acid content, and fatty acid composition of the LM did not differ among drinking water treatments. Supplementation of drinking water with GLYC or HFCS did not alter Warner-Bratzler shear force values or water-holding capacity (drip loss, cook shrink). Intramuscular mean adipocyte diameter was greater ( = 0.02) for steers offered HFCS compared with steers offered GLYC, with CON steers being intermediate. These differences in mean adipocyte size were related to changes in the adipocyte size distribution. There were greater proportions of small (20 to 30 µm) adipocytes in GLYC compared with HFCS and CON. In contrast, HFCS and CON had greater proportions of medium (40 to 50 µm) adipocytes than GLYC. The relative mRNA expression of lipogenic genes (acetyl Co-A carboxylase [ACC], fatty acid binding protein 4 [FABP4], fatty acid synthase [FASN], glycerol-3-phosphate acyltransferase [GPAT], retinol-binding protein 4 [RBP4], and stearoyl-CoA desaturase [SCD]), adipocyte differentiation genes (delta-like 1 homolog [DLK1]), and transcription factors (CCAAT/enhancer-binding protein α [C/EBPα], and PPARγ) was similar for GLYC and HFCS compared with CON. Longissimus glycogen and lactate concentrations and glycolytic potential were not affected by drinking water treatments. Overall, HFCS or GLYC supplementation via drinking water did not alter carcass or meat quality variables but did alter the size and distribution of intramuscular adipocytes. These results indicate that a longer supplementation time or a higher substrate level may be needed to obtain differences in meat quality.

Palmitoleic acid reduces intramuscular lipid and restores insulin sensitivity in obese sheep.

Obese sheep were used to assess the effects of palmitoleic (C16:1 cis-9) acid infusion on lipogenesis and circulating insulin levels. Infusion of 10 mg/kg body weight (BW)/day C16:1 intravenously in obese sheep reduced (P<0.01) weight gain by 77%. Serum palmitoleic levels increased (P<0.05) in a linear manner with increasing levels of C16:1 infusion. Cis-11 vaccenic (C18:1 cis-11) acid, a known elongation product of palmitoleic acid, was also elevated (P<0.05) in serum after 14 days and 21 days of infusion. Plasma insulin levels were lower (P<0.05) (10 mg/kg BW/day C16:1) than controls (0 mg/kg BW/day C16:1) at 14 days and 28 days of infusion. Infusion of C16:1 resulted in linear increases in tissue concentrations of palmitoleic, cis-11 vaccenic, eicosapentaenoic, and docosapentaenoic acids in a dose-dependent manner. Total lipid content of the semitendinosus (ST) muscle and mesenteric adipose tissue was reduced (P<0.01) in both 5 mg/kg and 10 mg/kg BW C16:1 dose levels. Total lipid content and mean adipocyte size in the longissimus muscle was reduced (P<0.05) in the 10 mg/kg BW C16:1 dose level only, whereas total lipid content and adipocyte size of the subcutaneous adipose tissue was not altered. Total lipid content of the liver was also unchanged with C16:1 infusion. Palmitoleic acid infusion upregulated (P<0.05) acetyl-CoA carboxylase (ACC), fatty acid elongase-6 (ELOVL6), and Protein kinase, AMP-activated, alpha 1 catalytic subunit, transcript variant 1 (AMPK) mRNA expressions in liver, subcutaneous adipose, and ST muscle compared to the controls. However, mRNA expression of glucose transporter type 4 (GLUT4) and carnitine palmitoyltransferase 1b (CPT1B) differed between tissues. In the subcutaneous adipose and liver, C16:1 infusion upregulated (P<0.05) GLUT4 and CPT1B, whereas these genes were downregulated (P<0.05) in ST muscle with C16:1 infusion. These results show that C16:1 infusion for 28 days reduced weight gain, intramuscular adipocyte size and total lipid content, and circulating insulin levels. These changes appear to be mediated through alterations in expression of genes regulating glucose uptake and fatty acid oxidation specifically in the muscles.